ArticlePloS one2026
A report on the mechanisms of sweeteners in four musculoskeletal disorders: Insights from network toxicology, molecular docking, and molecular dynamics simulations.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sweeteners are widely-studied food additives linked to metabolism and obesity, yet their musculoskeletal effects remain largely unknown.To investigate the potential effects of sweeteners on the musculoskeletal system, this study integrated network toxicology, molecular docking, and molecular dynamics simulations to systematically analyze the molecular associations between sweetener exposure and intervertebral disc degeneration, myositis, osteoarthritis, and osteoporosis. The results showed that sweeteners may affect musculoskeletal health by interfering with 35 core targets, which are primarily enriched in inflammatory responses, metabolic disorders, and related signaling pathways. Molecular docking revealed that sweeteners exhibited strong binding potential with these core targets, with mogroside and steviol glycosides showing particularly prominent predicted binding affinities. Molecular dynamics simulations further confirmed the binding stability of FASN, NOS2, and PCSK9 with these two sweeteners. This study provides a computational perspective on the potential disruption of musculoskeletal molecular networks by sweeteners, offering new targets and a theoretical basis for subsequent experimental validation and safety assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.